
Alternating Glivec and Stivarga Doesn't Improve Advanced GIST Outcomes
Alternating between treatment of Glivec (imatinib) and Stivarga (regorafenib) did not positively impact survival outcomes, leading to more toxicity and discontinuations among patients with advanced gastrointestinal stromal tumors (GIST), according to …